miR-340 also inhibits lung cancer cell proliferation by targeting CDK4 40; while it has been reported that CDK4 is involved in accelerating NSCLC cancer procession and combined inhibition of CDK4 could be effective to treat NSCLC 45. The gene discussed is CDK4; the disease is cancer.